Eluxadoline Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 2 pharmaceutical companies such as ABBVIE, ZYDUS PHARMS. It is marketed under 2 brand names, including VIBERZI, ELUXADOLINE. Available in 2 different strengths, such as 75MG, 100MG, and administered through 1 route including TABLET;ORAL.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 2 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"102422","ingredient":"ELUXADOLINE","trade_name":"VIBERZI","family_id":"39afc5086ae044698265","publication_number":"US7786158B2","cleaned_patent_number":"7786158","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-14","publication_date":"2010-08-31","legal_status":"Granted"} US7786158B2 Molecular 31 Aug, 2010 Granted 14 Mar, 2025
{"application_id":"102427","ingredient":"ELUXADOLINE","trade_name":"VIBERZI","family_id":"39afc5086ae044698265","publication_number":"US10213415B2","cleaned_patent_number":"10213415","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-14","publication_date":"2019-02-26","legal_status":"Patented case"} US10213415B2 Molecular 26 Feb, 2019 Patented case 14 Mar, 2025
{"application_id":"102426","ingredient":"ELUXADOLINE","trade_name":"VIBERZI","family_id":"39afc5086ae044698265","publication_number":"US9700542B2","cleaned_patent_number":"9700542","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-14","publication_date":"2017-07-11","legal_status":"Granted"} US9700542B2 Formulation 11 Jul, 2017 Granted 14 Mar, 2025
{"application_id":"102425","ingredient":"ELUXADOLINE","trade_name":"VIBERZI","family_id":"39afc5086ae044698265","publication_number":"US9205076B2","cleaned_patent_number":"9205076","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-14","publication_date":"2015-12-08","legal_status":"Granted"} US9205076B2 08 Dec, 2015 Granted 14 Mar, 2025
{"application_id":"102344","ingredient":"ELUXADOLINE","trade_name":"VIBERZI","family_id":"39afc5086ae044698265","publication_number":"US8772325B2","cleaned_patent_number":"8772325","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-14","publication_date":"2014-07-08","legal_status":"Granted"} US8772325B2 08 Jul, 2014 Granted 14 Mar, 2025
{"application_id":"102424","ingredient":"ELUXADOLINE","trade_name":"VIBERZI","family_id":"39afc5086ae044698265","publication_number":"US8609709B2","cleaned_patent_number":"8609709","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-14","publication_date":"2013-12-17","legal_status":"Granted"} US8609709B2 Molecular 17 Dec, 2013 Granted 14 Mar, 2025
{"application_id":"102423","ingredient":"ELUXADOLINE","trade_name":"VIBERZI","family_id":"39afc5086ae044698265","publication_number":"US8344011B2","cleaned_patent_number":"8344011","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-14","publication_date":"2013-01-01","legal_status":"Granted"} US8344011B2 01 Jan, 2013 Granted 14 Mar, 2025
{"application_id":"102340","ingredient":"ELUXADOLINE","trade_name":"VIBERZI","family_id":"a8004ea1a5794082bd9f","publication_number":"US9789125B2","cleaned_patent_number":"9789125","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-07-07","publication_date":"2017-10-17","legal_status":"Granted"} US9789125B2 Formulation 17 Oct, 2017 Granted 07 Jul, 2028
{"application_id":"102337","ingredient":"ELUXADOLINE","trade_name":"VIBERZI","family_id":"a8004ea1a5794082bd9f","publication_number":"US8691860B2","cleaned_patent_number":"8691860","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-07-07","publication_date":"2014-04-08","legal_status":"Granted"} US8691860B2 Molecular 08 Apr, 2014 Granted 07 Jul, 2028
{"application_id":"102304","ingredient":"ELUXADOLINE","trade_name":"VIBERZI","family_id":"a8004ea1a5794082bd9f","publication_number":"US9115091B2","cleaned_patent_number":"9115091","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-07-07","publication_date":"2015-08-25","legal_status":"Granted"} US9115091B2 Molecular Formulation 25 Aug, 2015 Granted 07 Jul, 2028
{"application_id":"102339","ingredient":"ELUXADOLINE","trade_name":"VIBERZI","family_id":"a8004ea1a5794082bd9f","publication_number":"US9364489B2","cleaned_patent_number":"9364489","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-07-07","publication_date":"2016-06-14","legal_status":"Patented case"} US9364489B2 14 Jun, 2016 Patented case 07 Jul, 2028
{"application_id":"102421","ingredient":"ELUXADOLINE","trade_name":"VIBERZI","family_id":"39afc5086ae044698265","publication_number":"US7741356B2","cleaned_patent_number":"7741356","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-05-27","publication_date":"2010-06-22","legal_status":"Court proceedings terminated"} US7741356B2 Molecular Formulation 22 Jun, 2010 Court proceedings terminated 27 May, 2029
{"application_id":"37079","ingredient":"ELUXADOLINE","trade_name":"VIBERZI","family_id":"07fe420859d948408b80","publication_number":"US11229627B1","cleaned_patent_number":"11229627","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-03-14","publication_date":"2022-01-25","legal_status":"Granted"} US11229627B2 Formulation 25 Jan, 2022 Granted 14 Mar, 2033
{"application_id":"7827","ingredient":"ELUXADOLINE","trade_name":"VIBERZI","family_id":"07fe420859d948408b80","publication_number":"US9675587B2","cleaned_patent_number":"9675587","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-03-14","publication_date":"2017-06-13","legal_status":"Granted"} US9675587B2 Formulation 13 Jun, 2017 Granted 14 Mar, 2033
{"application_id":"7848","ingredient":"ELUXADOLINE","trade_name":"VIBERZI","family_id":"07fe420859d948408b80","publication_number":"US11160792B2","cleaned_patent_number":"11160792","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-03-14","publication_date":"2021-11-02","legal_status":"Granted"} US11160792B2 Formulation 02 Nov, 2021 Granted 14 Mar, 2033
{"application_id":"7833","ingredient":"ELUXADOLINE","trade_name":"VIBERZI","family_id":"07fe420859d948408b80","publication_number":"US11007179B2","cleaned_patent_number":"11007179","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-03-14","publication_date":"2021-05-18","legal_status":"Granted"} US11007179B2 Formulation 18 May, 2021 Granted 14 Mar, 2033
{"application_id":"7822","ingredient":"ELUXADOLINE","trade_name":"VIBERZI","family_id":"07fe420859d948408b80","publication_number":"US11090291B2","cleaned_patent_number":"11090291","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-03-14","publication_date":"2021-08-17","legal_status":"Granted"} US11090291B2 Formulation 17 Aug, 2021 Granted 14 Mar, 2033
{"application_id":"7835","ingredient":"ELUXADOLINE","trade_name":"VIBERZI","family_id":"07fe420859d948408b80","publication_number":"US10188632B2","cleaned_patent_number":"10188632","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-03-14","publication_date":"2019-01-29","legal_status":"Granted"} US10188632B2 Formulation 29 Jan, 2019 Granted 14 Mar, 2033
{"application_id":"114401","ingredient":"ELUXADOLINE","trade_name":"VIBERZI","family_id":"07fe420859d948408b80","publication_number":"US20230293493A1","cleaned_patent_number":"12097187","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-03-14","publication_date":"2023-09-21","legal_status":"Granted"} US12097187B2 21 Sep, 2023 Granted 14 Mar, 2033
{"application_id":"26799","ingredient":"ELUXADOLINE","trade_name":"VIBERZI","family_id":"07fe420859d948408b80","publication_number":"US11311516B2","cleaned_patent_number":"11311516","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-03-14","publication_date":"2022-04-26","legal_status":"Granted"} US11311516B2 Formulation 26 Apr, 2022 Granted 14 Mar, 2033
{"application_id":"32939","ingredient":"ELUXADOLINE","trade_name":"VIBERZI","family_id":"07fe420859d948408b80","publication_number":"US11484527B2","cleaned_patent_number":"11484527","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-03-14","publication_date":"2022-11-01","legal_status":"Granted"} US11484527B2 01 Nov, 2022 Granted 14 Mar, 2033

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Eluxadoline

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.